Diabetic Neuropathy Newswire (Page 5)

Comprehensive Real-Time News Feed for Diabetic Neuropathy. (Page 5)

Results 81 - 100 of 482 in Diabetic Neuropathy

  1. Diabetic Neuropathy - Pipeline Review, H2 2014 - New Market Research ReportRead the original story

    Oct 4, 2014 | PR-inside.com

    This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action , route of administration and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.

    Comment?

  2. Effect of Fluoxetine on an Experimental Model of Diabetes-induced...Read the original story

    Oct 3, 2014 | CiteULike

    ... on blood glucose level and in prevention of diabetic neuropathic pain perception. Evaluation of diabetic neuropathy was performed after 9 weeks of single injection of streptozotocin (70 mg/kg i.v.) in rats. Blood glucose level, glycated haemoglobin, ...

    Comment?

  3. Influence of Murraya koenigii on experimental model of diabetes and progression of neuropathic pain.Read the original story

    Oct 3, 2014 | CiteULike

    The aim of the present study was to evaluate the effect of ethanolic extract of Murraya koenigii leaves on blood glucose level and in prevention or management of diabetic neuropathy. In the present study the diabetic neuropathy was developed 9 weeks after single injection of streptozotocin in rat.

    Comment?

  4. Spinal cord stimulation feasible for diabetic neuropathyRead the original story w/Photo

    Sep 30, 2014 | PhysOrg Weblog

    For patients with painful diabetic peripheral neuropathy , spinal cord stimulation is a successful treatment, according to a study published online Sept. 11 in Diabetes Care .

    Comment?

  5. Endexx Update on Proprietary Cannsumables DivisionRead the original story

    Sep 29, 2014 | BayStreet.ca

    ... pain management, Endexx is planning to support a case study with medical patients suffering from diabetic neuropathy. Endexx announced that it will be exhibiting at the Marijuana Business Conference & Expo in Las Vegas November 12-14. Endexx will ...

    Comment?

  6. College of Family Physicians gives doctors advice on prescribing medical potRead the original story w/Photo

    Sep 29, 2014 | The Winnipeg Free Press

    ... for nerve-damage pain caused by such conditions as multiple sclerosis, metastatic cancer, shingles, diabetic neuropathy and severe injury. But even in the case of such pain-causing conditions, doctors should consider using medical pot only after ...

    Comment?

  7. Stuart A. Schlegel: An unlikely journey to medical marijuanaRead the original story w/Photo

    Sep 26, 2014 | Santa Cruz Sentinel

    For years, I have had progressive numbness and fierce pain in my feet due to diabetic neuropathy. I shed almost 100 pounds last year and the diabetes went away, but the foot pain continued to worsen.

    Comment?

  8. Global Neuropathic Pain Treatment Drug Market Analysis and Forecast to 2022Read the original story

    Sep 27, 2014 | Emailwire.com

    ... range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain ...

    Comment?

  9. Neuropathic Pain Drug Market (Painful Diabetic Neuropathy,...Read the original story w/Photo

    Sep 26, 2014 | PRWeb

    Neuropathic Pain Drug Market (Painful Diabetic Neuropathy, Postherpetic and Trigeminal Neuralgia) Forecast to 2022 in New Report Available at MarketOptimizer.org MarketOptimizer.org adds "PharmaPoint: Neuropathic Pain - Global Drug Forecast and ...

    Comment?

  10. Physicians Committee OnlineRead the original story w/Photo

    Sep 25, 2014 | Physicians Committee for Responsible Medicine

    ... experiments at Wayne State University. Take Action > New Physicians Committee Study: Vegan Diet May Help Diabetic Neuropathy A low-fat vegan diet may reduce pain associated with diabetic neuropathy, according to findings the Physicians Committee ...

    Comment?

  11. Research and Markets: PharmaPoint: Neuropathic Pain - Global Drug...Read the original story

    Sep 25, 2014 | Customer Interaction Solutions

    This report provides an overview of three neuropathic pain indications - painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia - including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. It also gives annualized neuropathic pain therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.

    Comment?

  12. NeuroMetrix Reports Publication of Study Demonstrating that DPNCheck...Read the original story

    Sep 25, 2014 | Business Wire

    NeuroMetrix, Inc. , today reported publication of results from a DPNCheckA study conducted at the Diabetes Research Unit of the Ipswich Hospital NHS Trust in the United Kingdom. The study by Sharma and colleagues titled "Assessment of Diabetic Neuropathy Using a Point-of-Care Nerve Conduction Device Shows Significant Associations With the LDIFLARE Method and Clinical Neuropathy Scoring" was published in the Journal of Diabetes Science and Technology and is available at: "By using a clinical definition of DPN and also a comparison to a validated small fiber test, this study adds to the growing base of evidence supporting the effectiveness and utility of DPNCheck."

    Comment?

  13. NeuroMetrix CEO to Present at 29th Annual Meeting of Japan Society of Diabetic ComplicationsRead the original story w/Photo

    Sep 23, 2014 | Business Wire

    ... for the aldose reductase inhibitor, Epalrestat, a marketed pharmaceutical in Japan for patients with diabetic neuropathy with the diagnostic capability of the NeuroMetrix NC-stat DPNCheckA device for detection of peripheral neuropathies including ...

    Comment?

  14. Report Published: "Cebix Incorporated - Pharmaceuticals & Healthcare - Deals and Alliances Profile"Read the original story

    Sep 19, 2014 | PR-inside.com

    The company develops chronic replacement therapy for the treatment of diabetic neuropathy, nephropathy and retinopathy diseases. Its drug candidate drug Ersatta is a long-acting form of C-peptide, which is a molecule that is lacking in type 1 and some type 2 diabetic patients.

    Comment?

  15. Diabetes care hindered by patchy national dataRead the original story w/Photo

    Sep 19, 2014 | EurActiv.com

    ... show. Meanwhile, 10-20% die of kidney failure, 10% develop severe visual impairment and 50% suffer from diabetic neuropathy, it says.

    Comment?

  16. Physicians Committee OnlineRead the original story w/Photo

    Sep 17, 2014 | Physicians Committee for Responsible Medicine

    ... and even certain forms of cancer. Seven Foods > New Physicians Committee Study: Vegan Diet May Help Diabetic Neuropathy A low-fat vegan diet may reduce pain associated with diabetic neuropathy, according to findings the Physicians Committee ...

    Comment?

  17. Glenmark Pharmaceuticals's TRPA1 Antagonist 'GRC 17536' Shows...Read the original story

    Sep 17, 2014 | BioSpace

    Glenmark's first in class TRPA1 antagonist, GRC 17536, has shown positive data in a Phase 2a proof of concept study in patients with painful diabetic neuropathy Glenmark Pharmaceuticals today announced that its first in class Transient Receptor Potential Ankyrin 1 antagonist, GRC 17536 has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept study conducted on 138 patients in Europe and India. A statistically significant and clinically relevant response was seen in a prospectively-identified, substantial sub-group of patients with moderate to severe pain who had relatively intact sensory responses as detected by a standardized testing methodology.

    Comment?

  18. Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept StudyRead the original story

    Sep 17, 2014 | Applied Clinical Trials

    Glenmark's first in class TRPA1 antagonist, GRC 17536, has shown positive data in a Phase 2a proof of concept study in patients with painful diabetic neuropathy Glenmark Pharmaceuticals today announced that its first in class Transient Receptor Potential Ankyrin 1 antagonist, GRC 17536 has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept study conducted on 138 patients in A statistically significant and clinically relevant response was seen in a prospectively-identified, substantial sub-group of patients with moderate to severe pain who had relatively intact sensory responses as detected by a standardized testing methodology.

    Comment?

  19. Key antioxidant and trace mineral compounds that improve blood sugar stabilityRead the original story w/Photo

    Sep 16, 2014 | NewsTarget.com

    ... resulting tissue damage in the body. Glycation is the process that leads to atrocious conditions such as diabetic neuropathy, optic nerve destruction and resulting diabetic blindness and diabeties-induced kidney failure. Controlling glycation and ...

    Comment?

  20. Japan microvascular complications of diabetes market growth fueled by ...Read the original story w/Photo

    Sep 16, 2014 | PR-inside.com

    ... rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors. The growth will be fueled mainly by ...

    Comment?